A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs TPI 287 (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Adverse reactions
  • Acronyms TPI-287-4RT
  • Most Recent Events

    • 03 Nov 2017 Data were presented in a Cortice Biosciences Media Release.
    • 03 Nov 2017 According to a Cortice Biosciences media release, data were presented at the 2017 Clinical Trials on Alzheimers Disease (CTAD) conference.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top